Porfiromycin
notability.(January 2023) ) |
Clinical data | |
---|---|
Trade names | Promycin[1] |
ATC code | |
Identifiers | |
| |
JSmol) | |
| |
|
Porfiromycin is an N-methyl
antineoplastic antibiotic, mitomycin C, which is isolated from various Streptomyces bacterial species.[2] As an antineoplastic agent, it is under investigation for the treatment of cancer, particularly head and neck cancer.[1]
Porfiromycin works by generating
oxygen radicals and alkylating DNA, resulting in interstrand cross-links and single-strand breaks. This inhibits DNA synthesis and leads to the death of cancer cells. It has a higher toxicity towards hypoxic cells, making it an attractive option for cancer treatment.[2]
Porfiromycin can increase the risk of methemoglobinemia when taken with certain medications.[1] It belongs to the class of compounds known as mitomycins, which are characterized by their aziridine ring linked to a 7-amino-6-methyl-cyclohexa[b]pyrrolizine-5,8-dione structure.[1]
References
- ^ a b c d e "Porfiromycin". Retrieved January 8, 2022.
- ^ a b c "Porfiromycin (Code C763)". Retrieved January 8, 2022.